Clinical Trial Update: Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis [Phase 4]

View source ↗

Summary

This clinical trial update indicates that sparsentan is being studied in Phase 4 for posttransplant immunoglobulin A nephropathy and focal segmental glomerulosc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Immunoglobulin Nephropathy

Drugs mentioned

• Sparsentan (sparsentan)

Snippet

Sponsor: Travere Therapeutics, Inc. | Conditions: Proteinuria, Immunoglobulin A (IgA) Nephropathy | Phase 4 | Status: RECRUITING